PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Our offering

At Evolve, we provide specialised IP strategy services tailored to the unique needs of pharmaceutical and biotechnology companies at every stage of development. Our approach combines scientific expertise with commercial insight to deliver practical intellectual property solutions that drive business value. We understand that effective IP strategy must be both deeply rooted in the science and adapt alongside your company’s growth.

With extensive industry experience and technical knowledge, we are passionate about supporting our clients to realise the full potential of their innovations.

 

Find out more

Evolve IP is able to offer commercially focused, strategic, and clear advice on complex patent portfolios

The team are thoughtful and intuitive and provide a personable service.

Evolve are friendly and knowledgeable and provide practical advice.

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

I recommend Evolve for chemical/pharma patent issues – whether prosecution or complex FTO or loss of exclusivity considerations.

Evolve Intellectual Property offers expertise in patent portfolio management, strategic planning and formalities.

Evolve Intellectual Property is a growing firm, with an excellent reputation.

Evolve is a refreshing change to the traditional patent attorney form approach – much more nimble and responsive.

Fractional in-house

Do you need experienced IP leadership without the overhead of a full-time in-house team?

Our fractional in-house service delivers the senior head of IP expertise you require on a flexible and cost-effective basis, allowing you to scale your IP function precisely when and how you need it. We understand the critical role intellectual property plays in your growth and offer a tailored approach to align your IP strategy directly with your overarching business objectives. Our fractional in-house service seamlessly integrates with your existing team, becoming a trusted partner in managing your day-to-day IP needs. By working with us you will benefit from strategically managed intellectual property helping you to foster innovation, secure investment and gain a competitive edge.

With Evolve you access experienced IP leadership when you need it. Think of us as your dedicated, senior IP resource, readily available to handle the operational complexities while providing expert strategic direction.

Find out more

Sectors

Our team’s combined experience spans traditional pharmaceuticals to cutting-edge advanced therapies, providing you with guidance that is both scientifically informed and commercially pragmatic.

 

Find out more
  • Pharmaceuticals
  • Biotech
  • Biologics
  • Cell & gene therapy
  • AI drug discovery
  • Chemistry

Insights

Visit Evolve Insights for our latest articles and webinars on key emerging trends and strategic considerations in pharmaceutical IP.

Read more

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector field is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025 (see Evolve Insights), we review the most impactful decisions of the year relating to clinical-stage inventions. 

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.

First use of G 1/24 to broaden clear claim language (T 1849/23)

  • 16th November 2025
This significant decision is the first from the Boards of Appeal to apply G 1/24 to the use of information from the description to broaden otherwise clear claim language.

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.

Our team

Evolve is a pharmaceutical specialist IP firm, offering comprehensive intellectual property services built on the experience of our attorneys in both in-house and private practice settings. Evolve is built on the deep expertise of our qualified attorneys in the pharmaceutical and biotech sector. With our personalized approach, scientific backgrounds and industry insights, we deliver tailored and pragmatic IP solutions for our pharmaceutical and biotechnology clients.

Meet the team

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us